Several studies presented at this year's American Society of Clinical Oncology (ASCO) annual meeting highlighted emerging strategies for hormone receptor (HR)-positive, HER2-negative metastatic breast cancer, including early intervention for ESR1 mutations, oral selective estrogen receptor degraders (SERDs), and novel targeted combinations.
MedPage Today brought together three expert leaders in the field: Moderator Hope S. Rugo, MD, of the City of Hope Comprehensive Cancer Center in Duarte, California, is joined by William J. Gradishar, MD, of Northwestern University Feinberg School of Medicine in Chicago, and Paolo Tarantino, MD, PhD, of Dana-Farber Cancer Institute in Boston, for a virtual roundtable discussion. In this second of four exclusive episodes, the panel discusses the implications of SERENA-6, VIKTORIA-1, and evERA, and how an expanding list of treatment options may reshape sequencing decisions in metastatic disease.
Click here to watch the other videos from this series.
Following is a transcript of their remarks:
Rugo: Let's go on and talk about another area that's actually probably one of the biggest controversies right now in our treatment of hormone receptor-positive breast cancer.
